Goldman Sachs analyst Andrea Tan initiated coverage of AbCellera with a Buy rating and $30 price target. The company is positioned at the intersection of biotech and tech and is developing a "best-in-class" antibody discovery platform with the goal of becoming the centralized operating system for drug developers, Tan tells investors in a research note. The analyst is constructive on AbCellera’s partnership model, saying it supports a large and diverse portfolio without the risk normally associated with drug development.
Published first on TheFly
See today’s best-performing stocks on TipRanks >>
Read More on ABCL:
- AbCellera, Rallybio enter pact for novel antibody-based therapeutics
- Bebtelovimab losing EUA has ‘limited impact’ on Piper model for AbCellera
- FDA announces bebtelovimab not currently authorized in any U.S. region
- AbCellera down 7% after FDA announces bebtelovimab not authorized in U.S.
- AbCellera reports Q3 EPS 9c, consensus 4c
